Review anchor
Voltage-gated inwardly rectifying potassium channel KCNH2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Voltage-gated inwardly rectifying potassium channel KCNH2
CHEMBL240
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Voltage-gated inwardly rectifying potassium channel KCNH2 as ChEMBL target CHEMBL240, mapped to UniProt Q12809. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL240
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q12809
Voltage-gated inwardly rectifying potassium channel KCNH2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Voltage-gated inwardly rectifying potassium channel KCNH2 matters
Voltage-gated inwardly rectifying potassium channel KCNH2 is reviewed as Voltage-gated inwardly rectifying potassium channel KCNH2 (UniProt Q12809); Voltage-gated inwardly rectifying potassium channel KCNH2 shows approved-linked disease relevance led by atrial fibrillation. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 230 approved drugs, 25517 compounds, and 4562 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Voltage-gated inwardly rectifying potassium channel KCNH2
Voltage-gated inwardly rectifying potassium channel KCNH2 Sequence length is 1159 aa.
Review this target as Voltage-gated inwardly rectifying potassium channel KCNH2, mapped to UniProt Q12809. Sequence length is 1159 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q12809
Protein
Disease context
atrial fibrillation
Voltage-gated inwardly rectifying potassium channel KCNH2 shows approved-linked disease relevance led by atrial fibrillation. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMIODARONE HYDROCHLORIDE, AZD1305, AZD7009.
Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include AMIODARONE HYDROCHLORIDE, AZD1305, AZD7009, DOFETILIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
6 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 230 approved drugs, 25517 compounds, and 4562 assays for this target. The dominant activity type is IC50. CHEMBL4595328 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL4595328 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
230 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Voltage-gated inwardly rectifying potassium channel KCNH2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q12809, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why atrial fibrillation is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
25517
Total Compounds
4562
Total Assays
230
Approved Drugs
IC50: 18550.0, KI: 3649.0, EC50: 252.0, KD: 47.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4595328
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL327980
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL1257821
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL5432371
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL1257820
|
9.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CEFIDEROCOL
CHEMBL3989974
|
2019 |
|
|
COCAINE
CHEMBL370805
|
2017 |
|
|
PIMAVANSERIN
CHEMBL2111101
|
2016 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
BEDAQUILINE
CHEMBL376488
|
2012 |
|
|
RILPIVIRINE
CHEMBL175691
|
2011 |
|
|
LUMEFANTRINE
CHEMBL38827
|
2009 |
|
|
DRONEDARONE
CHEMBL184412
|
2009 |
|
|
ELTROMBOPAG
CHEMBL461101
|
2008 |
|
|
LAPATINIB
CHEMBL554
|
2007 |
|
|
NEBIVOLOL
CHEMBL434394
|
2007 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
PALIPERIDONE
CHEMBL1621
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DARIFENACIN
CHEMBL1346
|
2004 |
|
|
SOLIFENACIN
CHEMBL1734
|
2004 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
ZIPRASIDONE
CHEMBL708
|
2001 |
|
|
DOFETILIDE
CHEMBL473
|
1999 |
|
|
CITALOPRAM
CHEMBL549
|
1998 |
|
|
TOLTERODINE
CHEMBL1382
|
1998 |
|
|
MIZOLASTINE
CHEMBL94454
|
1998 |
|
|
MIBEFRADIL
CHEMBL45816
|
1997 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
AZELASTINE
CHEMBL639
|
1996 |
|
|
DONEPEZIL
CHEMBL502
|
1996 |
|
|
IBUTILIDE
CHEMBL533
|
1995 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
LORATADINE
CHEMBL998
|
1993 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
CISAPRIDE MONOHYDRATE
CHEMBL1200788
|
1993 |
|
|
HALOFANTRINE
CHEMBL1107
|
1992 |
|
|
ONDANSETRON
CHEMBL46
|
1991 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
BEPRIDIL
CHEMBL1008
|
1990 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
PROPAFENONE
CHEMBL631
|
1989 |
|
|
ASTEMIZOLE
CHEMBL296419
|
1988 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
AMSACRINE
CHEMBL43
|
1987 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
TERODILINE
CHEMBL363295
|
1986 |
Source Header